Ovid Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Mar 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 18, 2026
OVID$2.850.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| (in thousands, except share and per share data) | For the Year Ended December 31, 2025 | For the Year Ended December 31, 2024 |
|---|---|---|
| Revenue: | ||
| License and other revenue | $7,252 | $566 |
| Total revenue | 7,252 | 566 |
| Operating expenses: | ||
| Research and development | 25,582 | 36,767 |
| General and administrative | 24,109 | 25,684 |
| Total operating expenses | 49,691 | 62,451 |
| Loss from operations | (42,439) | (61,885) |
| Other income (expense), net | 25,026 | 35,452 |
| Loss before provision for income taxes | (17,414) | (26,433) |
| Provision for income taxes | — | — |
| Net loss | $(17,414) | $(26,433) |
| Net loss per share of Series A preferred stock, basic and diluted | $(232.47) | $(366.33) |
| Weighted-average Series A preferred stock shares outstanding, basic and diluted | 1,171 | 1,250 |
| Net loss per share of common stock, basic and diluted | $(0.23) | $(0.37) |
| Weighted-average common stock shares outstanding, basic and diluted | 73,735,606 | 70,905,422 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.